KCL leads first guidelines on immune monitoring for hard-to-treat blood cancer
Myelodysplastic syndromes are a group of blood cancers that currently affect more than 7,000 people in the UK
Read More
Tag: immune response
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
